MA28587B1 - Procede de purification de conjugues d'albumine - Google Patents

Procede de purification de conjugues d'albumine

Info

Publication number
MA28587B1
MA28587B1 MA29463A MA29463A MA28587B1 MA 28587 B1 MA28587 B1 MA 28587B1 MA 29463 A MA29463 A MA 29463A MA 29463 A MA29463 A MA 29463A MA 28587 B1 MA28587 B1 MA 28587B1
Authority
MA
Morocco
Prior art keywords
albumin
albumin conjugates
conjugates
solution
unconjugated
Prior art date
Application number
MA29463A
Other languages
English (en)
Inventor
Nathalie Bousquet-Gagnon
Omar Quraishi
Dominique P Bridon
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35196920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28587(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Publication of MA28587B1 publication Critical patent/MA28587B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA29463A 2004-04-23 2006-11-20 Procede de purification de conjugues d'albumine MA28587B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56522804P 2004-04-23 2004-04-23

Publications (1)

Publication Number Publication Date
MA28587B1 true MA28587B1 (fr) 2007-05-02

Family

ID=35196920

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29463A MA28587B1 (fr) 2004-04-23 2006-11-20 Procede de purification de conjugues d'albumine

Country Status (25)

Country Link
US (3) US7307148B2 (fr)
EP (3) EP2100904B1 (fr)
JP (1) JP2007535507A (fr)
CN (1) CN1956998B (fr)
AT (2) ATE433999T1 (fr)
AU (1) AU2005235634B2 (fr)
BR (1) BRPI0510117A (fr)
CA (1) CA2564031A1 (fr)
DE (2) DE602005014969D1 (fr)
DK (2) DK2100904T3 (fr)
EA (1) EA011168B1 (fr)
ES (2) ES2347902T3 (fr)
HK (2) HK1096102A1 (fr)
HR (1) HRP20060362A2 (fr)
IL (1) IL178369A0 (fr)
MA (1) MA28587B1 (fr)
MX (1) MXPA06012260A (fr)
NO (1) NO20065037L (fr)
PL (2) PL1745078T3 (fr)
PT (2) PT2100904E (fr)
RS (1) RS20060578A (fr)
SI (2) SI1745078T1 (fr)
TN (1) TNSN06340A1 (fr)
WO (1) WO2005103087A1 (fr)
ZA (1) ZA200608475B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ES2209885T3 (es) * 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1264840B1 (fr) * 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Peptides hybrides inhibiteurs à action prolongée des infections virales
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
EP1360202B1 (fr) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
WO2002096935A2 (fr) 2001-05-31 2002-12-05 Conjuchem, Inc. Inhibiteurs peptidiques de fusion longue duree contre les infections a vih
CA2565658A1 (fr) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Composes pour cible virale specifique
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP1976876A4 (fr) * 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc Procédé de production de conjugués d'albumine préformés et agent thérapeutique
WO2008047241A2 (fr) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Peptides du facteur libérateur de corticotrophine modifiés et leurs utilisations
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
EP2147016A2 (fr) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Dérivés d'acide cystéique de peptides antiviraux
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
CA2708762A1 (fr) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation de conjugues de peptides insulinotropes
EP2247298B1 (fr) * 2007-12-31 2016-08-31 New York University Contrôle de la fusion de membrane hôte virale avec des hélices artificielles à base de succédané de liaison hydrogène
WO2009121884A1 (fr) 2008-04-01 2009-10-08 Novo Nordisk A/S Conjugués insuline-albumine
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
EP2504019A2 (fr) 2009-11-25 2012-10-03 ArisGen SA Composition à libération par voie muqueuse contenant un peptide, un agent de couronne et/ou un contre-ion
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
TR201810856T4 (tr) * 2014-01-10 2018-08-27 Synthon Biopharmaceuticals Bv CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul.
JP6830355B2 (ja) * 2014-01-31 2021-02-17 イクセラ，インコーポレイテッド バイオマーカーとしての共有結合した代謝物質
US9616109B2 (en) * 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN105111306A (zh) * 2015-08-28 2015-12-02 北京工业大学 美洲短吻鳄白蛋白的分离方法
CN109311910B (zh) 2016-03-24 2022-02-01 杜兰教育基金委员会 他克莫司偶联物、其组合物、及其用途
SG11202002563WA (en) * 2017-09-28 2020-04-29 Hanmi Pharmaceutical Co Ltd Long-acting conjugates of glp-2 derivatives
CN108840922A (zh) * 2018-06-04 2018-11-20 河北常山生化药业股份有限公司 分离白蛋白非结合物、白蛋白结合物和小分子化合物的方法
CN108977423A (zh) * 2018-08-17 2018-12-11 集美大学 一种从猪肺中分离提纯血管紧张素转化酶的方法
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109721653B (zh) * 2019-03-05 2023-02-03 嘉兴学院 一种胰高血糖素样肽-1片段类似物及其应用
CN115397846A (zh) * 2020-03-06 2022-11-25 昆山新蕴达生物科技有限公司 疏水性修饰的白蛋白及其制备方法和用途
WO2021222759A1 (fr) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Conjugués de médicament à base d'albumine et leur utilisation pour le traitement du cancer
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4745100A (en) 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4859604A (en) 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
WO1992017492A1 (fr) 1991-04-05 1992-10-15 Genentech, Inc. INHIBITEURS DE L'AGREGATION PLAQUETTAIRE PRESENTANT UNE SPECIFICITE ELEVEE POUR GP IIbIII¿a?
US5103233A (en) 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
DE69332948T2 (de) 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5807827A (en) 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US20020018751A1 (en) 1993-10-15 2002-02-14 BRIDON Dominique P. Cellular and serum protein anchors for diagnostic imaging
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK145493D0 (da) 1993-12-23 1993-12-23 Dako As Antistof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
EP0759768A4 (fr) 1994-04-07 2000-08-09 Proteinix Company Polypeptide intestinal vasoactif
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
CA2157219C (fr) * 1994-08-31 2010-10-05 Munehiro Noda Procede pour la purification d'albumine de serum humain recombinante
US5939390A (en) 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
TR199802789T2 (xx) 1996-06-05 1999-03-22 Boehringer Mannheim Gmbh Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2359031T3 (es) 1996-08-08 2011-05-17 Amylin Pharmaceuticals, Inc. Composición farmacéutica que comprende un péptido de exendina-4.
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998011437A1 (fr) 1996-09-16 1998-03-19 Conjuchem, Inc. Bibliotheques de marquage d'affinite avec groupes partants marques
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE366584T1 (de) 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
CN1268639C (zh) * 1996-11-15 2006-08-09 基因技术股份有限公司 神经营养蛋白的纯化
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
EP1056474B1 (fr) 1997-11-07 2002-06-12 ConjuChem, Inc. Marqueurs d'affinite pour la serum-albumine humaine
WO1999024076A2 (fr) 1997-11-07 1999-05-20 Conjuchem, Inc. Agents diagnostiques et therapeutiques derivatises par salicylate
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056775B1 (fr) 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de gpl-1 et de l'extendine au profil d'action etendu
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
EP1140145B2 (fr) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Nouvelles formulations d'agonistes de l'exendine et modes d'administration
WO2000041548A2 (fr) 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Methodes de suppression du glucagon
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1264840B1 (fr) * 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Peptides hybrides inhibiteurs à action prolongée des infections virales
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
WO2000078333A2 (fr) 1999-06-21 2000-12-28 Eli Lilly And Company Utilisation combinee de thiazolidinediones et de peptide-1 de type glucagone et d'agonistes de ces derniers pour traiter l'instabilite metabolique associee aux diabetes non insulino-dependants.
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
WO2001066417A1 (fr) * 2000-03-09 2001-09-13 Crisplant A/S Dispositif de decharge et d'empilement
CA2405557C (fr) * 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Proteines hybrides d'albumine
KR100518046B1 (ko) 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
WO2002034285A2 (fr) 2000-10-20 2002-05-02 Coolidge Thomas R Traitement du myocarde hibernant et de la cardiomiopathie diabétique par un peptide glp-1
WO2002047716A2 (fr) 2000-12-13 2002-06-20 Eli Lilly And Company Regime de traitement chronique utilisant des peptides insulinotropiques du type glucagon
CA2435563A1 (fr) * 2001-02-02 2002-08-15 Conjuchem Inc. Derives du facteur de liberation de l'hormone de croissance de longue duree
EP1360202B1 (fr) * 2001-02-16 2008-05-21 ConjuChem Biotechnologies Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
WO2002096935A2 (fr) 2001-05-31 2002-12-05 Conjuchem, Inc. Inhibiteurs peptidiques de fusion longue duree contre les infections a vih
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
BRPI0417684A (pt) * 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
EA200601959A1 (ru) 2007-04-27
ES2347902T3 (es) 2010-11-22
US7307148B2 (en) 2007-12-11
WO2005103087A1 (fr) 2005-11-03
ATE473244T1 (de) 2010-07-15
CN1956998B (zh) 2012-12-12
TNSN06340A1 (en) 2008-02-22
DE602005014969D1 (de) 2009-07-30
DE602005022239D1 (de) 2010-08-19
PT1745078E (pt) 2009-09-17
EP2230257A1 (fr) 2010-09-22
RS20060578A (en) 2008-11-28
CN1956998A (zh) 2007-05-02
PT2100904E (pt) 2010-09-24
DK1745078T3 (da) 2009-10-26
PL1745078T3 (pl) 2009-12-31
PL2100904T3 (pl) 2011-05-31
US20050267293A1 (en) 2005-12-01
ATE433999T1 (de) 2009-07-15
CA2564031A1 (fr) 2005-11-03
MXPA06012260A (es) 2006-12-15
DK2100904T3 (da) 2010-11-08
SI2100904T1 (sl) 2010-10-29
HRP20060362A2 (en) 2007-03-31
BRPI0510117A (pt) 2007-09-25
EP1745078A1 (fr) 2007-01-24
EP1745078A4 (fr) 2007-08-01
ES2328591T3 (es) 2009-11-16
SI1745078T1 (sl) 2009-12-31
HK1096102A1 (en) 2007-05-25
EA011168B1 (ru) 2009-02-27
EP2100904B1 (fr) 2010-07-07
US20120022234A1 (en) 2012-01-26
NO20065037L (no) 2007-01-11
US20080146783A1 (en) 2008-06-19
JP2007535507A (ja) 2007-12-06
AU2005235634A1 (en) 2005-11-03
ZA200608475B (en) 2007-11-28
AU2005235634B2 (en) 2011-10-20
HK1136305A1 (en) 2010-06-25
EP1745078B1 (fr) 2009-06-17
EP2100904A1 (fr) 2009-09-16
IL178369A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
MA28587B1 (fr) Procede de purification de conjugues d'albumine
WO2007109163A3 (fr) Tampon de lavage et procédé d'utilisation correspondant
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
SG162806A1 (en) Methods of purifying anti a beta antibodies
DK0489423T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelsen af disse forbindelser som lægemidler
ATE98509T1 (de) Integriertes verfahren fuer die entfernung von schwefelverbindungen aus fluidstroemen.
DK1156835T3 (da) Fremgangsmåde til radiomærkning af proteiner med Yttrium-90
MX2009005012A (es) Una forma pura de rapamicina y procedimiento para la recuperacion y purificacion de la misma.
PL1841863T3 (pl) Sposób oczyszczania czynnika VII
DK1718673T3 (da) Fremgangsmåde til rensning af albumin omfattende et nanofiltreringstrin, oplösning og sammensætning til terapeutisk anvendelse, som indeholder det
DK0646594T3 (da) Fremgangsmåde til rensning af proteiner
DE602005020049D1 (de) Verfahren zur trennung und reinigung von hydrocodon durch präparative chromatographie
BR0107847A (pt) Processo para purificar ácido (met) acrìlico por cristalização
ATE541037T1 (de) Verfahren zur trennung und reinigung von nukleinsäure
KR840003422A (ko) 균질한 인체 면역 인터페론의 제조방법
WO2005014779A3 (fr) Purification de la cyclodextrine par affinite
EA200801195A1 (ru) Способ концентрирования, очистки и удаления прионового белка
FR2889078B1 (fr) Nouvelle methode de chromatographie d'affinite d'antithrombine iii
SE0201207D0 (sv) A process for production of a regioselective membrane
ATE540974T1 (de) Reinigung des rekombinanten menschlichen faktors xiii
ATE441658T1 (de) Verfahren zur reinigung von 5'-geschützten 2'- deoxypurin nukleosiden
FI894235A (fi) Foerfarande foer aotervinning av proteiner ur en loesning.
KR830001368A (ko) 우로키나제의 정제 및 농축방법